Shen Yuanyuan, Huang Yuanhao, Ouyang Yuqin, Xiang Xinyue, Chu Xuehui, Zhang Bingqing, Han Tao, Tang Wenjuan, Feng Wenhuan
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Zhongshan Road 321, Nanjing, 210008, China.
Branch of National Clinical Research Center for Metabolic Diseases, Zhongshan Road 321, Nanjing, 210008, China.
Diabetes Ther. 2024 Dec;15(12):2499-2513. doi: 10.1007/s13300-024-01643-1. Epub 2024 Oct 23.
The safety and efficacy of liraglutide as a weight loss intervention in individuals who remain obese within 1 year post-metabolic surgery remain unclear. This study aimed to evaluate the effects and safety of liraglutide (1.8 mg) in patients with persistent obesity at 6 months postoperatively.
This retrospective cohort study included 61 patients who remained obese (body mass index [BMI] ≥ 28.0 kg/m) at 6 months postoperatively. Among these patients, 27 were treated with 1.8 mg of liraglutide for 12 weeks, whereas 34 served as controls. The primary endpoint was the change in total weight loss (%TWL) after 24 weeks. Changes in weight, BMI, complications, and adverse events were also assessed.
The liraglutide group showed a greater reduction in %TWL than the control group (11.6% ± 1.1% vs. 4.9% ± 1.0%), with an estimated treatment difference of 6.6% (95% confidence interval [CI], 3.7-9.6%, P < 0.01). The adjusted mean differences in the reduction of weight and BMI between the liraglutide and control groups were - 6.2 kg (95% CI - 8.9 to - 3.4, P < 0.01) and - 3.0 kg/m (95% CI - 4.2 to - 1.7, P < 0.01), respectively. The liraglutide group exhibited increased rates of remission in non-alcoholic fatty liver disease and hypertension. No serious adverse reactions were observed.
For patients who remained obese at 6 months postoperatively, 12-week liraglutide treatment resulted in increased weight loss, improved metabolic control, and high rate of remission for obesity-related metabolic diseases after 24 weeks. Earlier and more timely adjuvant weight loss medication intervention based on BMI within 1 year postoperatively may enhance weight loss after metabolic surgery. Graphical abstract available for this article.
利拉鲁肽作为代谢手术后1年内仍肥胖个体的减肥干预措施，其安全性和有效性尚不清楚。本研究旨在评估利拉鲁肽（1.8毫克）对术后6个月持续性肥胖患者的疗效和安全性。
这项回顾性队列研究纳入了61例术后6个月仍肥胖（体重指数[BMI]≥28.0千克/平方米）的患者。其中，27例接受1.8毫克利拉鲁肽治疗12周，34例作为对照。主要终点是24周后总体重减轻百分比（%TWL）的变化。还评估了体重、BMI、并发症和不良事件的变化。
利拉鲁肽组的%TWL降低幅度大于对照组（11.6%±1.1%对4.9%±1.0%），估计治疗差异为6.6%（95%置信区间[CI]，3.7-9.6%，P<0.01）。利拉鲁肽组与对照组体重和BMI降低的调整后平均差异分别为-6.2千克（95%CI-8.9至-3.4，P<0.01）和-
